Donald Durden, M.D., Ph.D.

Locations

3020 Children's Way
MC 5035
San Diego, CA 92123

Specialty

Hematology/Oncology

Organization

Rady Children's Specialists of San Diego

Medical Group / IPA

Rady Children's Specialists

Board Certifications

Pediatric Hematology/Oncology, Pediatrics

Gender

M

Bio

A renowned physician-scientist, Dr. Donald Durden is associate director for pediatric oncology at the UC San Diego Moores Cancer Center and a professor of pediatrics at UC San Diego School of Medicine.

In 2009, Dr. Durden joined UC San Diego from Emory University School of Medicine in Atlanta, where he was professor of pediatric oncology and hematology and scientific director of basic and translational research at the AFLAC Cancer Center & Blood Disorders Service at Children's Healthcare of Atlanta and Emory University. Well known as an expert in signal transduction pathways, Dr. Durden discovered the role of PI3K/PTEN, the main cell-signaling pathway for blood vessel growth, cell survival, programmed cell death and cell proliferation.

Located within the Moores Cancer Center on the UC San Diego campus, the Durden Laboratory is part of a multidisciplinary neuro-oncology team aimed at designing new approaches for brain tumor therapy. Dr. Durden has trained multiple undergraduate and graduate students, medical fellows and postdoctorate students.

Dr. Durden received his Bachelor of Science in microbiology from the University of South Florida and his medical and doctorate degrees from the University of Miami School of Medicine. He completed his pediatric residency and hematology/oncology fellowship at University of Washington and Fred Hutchinson Cancer Center. Dr. Durden received his postdoctoral training in the laboratory of Jonathan Cooper at the Fred Hutchinson Cancer Center in Seattle, where he studied signaling networks that regulate cancer cell growth and metastasis.

Publications

The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity.
Nguyen HA, Durden DL, Lavie A

Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL

Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY

Vascular remodeling underlies rebleeding in hemophilic arthropathy.
Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A

Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S, Singh AR, Durden DL

Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model.
Singh AR, Joshi S, George E, Durden DL

A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S, Singh AR, Zulcic M, Durden DL

MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Joshi S, Singh AR, Durden DL

A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis.
Joshi S, Singh AR, Zulcic M, Durden DL

PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment.
Singh AR, Peirce SK, Joshi S, Durden DL

Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo.
Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL

Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL

PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT

Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL

Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma.
Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R

Regulation of XIAP translation and induction by MDM2 following irradiation.
Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ

Expression of RAC2 in endothelial cells is required for the postnatal neovascular response.
De P, Peng Q, Traktuev DO, Li W, Yoder MC, March KL, Durden DL

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.

Rady Children's updates the Doctor Finder annually. We are not responsible for omissions or errors. Prior to making an appointment, please be sure to check with your health plan to confirm coverage. If you see an error or omission on a physician's profile page, please contact us at refsvc@rchsd.org.